10.15887/j.cnki.13-1389/r.2016.01.040 188 Soro-PaavonenA.WatsonA
Pediatr Nephrol 5:454460 Maxwell H, Nair DR, Dalton RN, Rigden SP, Rees L (1995) Differential effects of recombinant human growth hormone on glomerular filtration rate and renal plasma flow in chronic renal failure
The mean (SD) number of medications prescribed per patient was 1.5 (1.4), with a median of 1 and a range of 0 to 6
Another drug of this class, dapagliflozin, is being examined in the DEAN trial, a phase 3 RCT addressing NASH in patients with DM2
2017 Aug;69(8):578-594
(For all of last year, Mounjaro generated $482.5 million in revenues.) Based in Berkeley, CA, Carmot focuses on developing drugs for metabolic diseases that include obesity and diabetes, as well as Prader-Willi syndrome, the disease targeted by Carmots sole disclosed preclinical candidate CT-PYY, a long-acting PYY analog delivered as an injectable peptide